Page 138 - 《中国药房》2022年11期

open-label study of afatinib plus vinorelbine in patients therapy of advanced non-small cell lung cancer：a phase
with solid tumours overexpressing EGFR and/or HER2[J]. Ⅱ study[J]. Lung Cancer，2008，60（3）：387-392.
Br J Cancer，2018，118（3）：344-352. [39] CAMPONE M，FUMOLEAU P，DELECROIX V，et al.
[28] PUJOL J L，VIENS P，REBATTU P，et al. Gefitinib Phase Ⅰ dose-finding and pharmacokinetic study of
（IRESSA） with vinorelbine or vinorelbine/cisplatin for docetaxel and vinorelbine as first-line chemotherapy for
chemotherapy-naive non-small cell lung cancer patients metastatic breast cancer[J]. Ann Oncol，2001，12（7）：909-
[J]. J Thorac Oncol，2006，1（5）：417-424. 918.
[29] BUGAT R，VARIOL P，ROCHÉ H，et al. The effects of [40] DELVA R，PIENKOWSKI T，TUBIANA N，et al. Oral
food on the pharmacokinetic profile of oral vinorelbine[J]. vinorelbine/paclitaxel combination treatment of metastatic
Cancer Chemother Pharmacol，2002，50（4）：285-290. breast cancer：a phase Ⅰstudy[J]. Cancer Chemother Phar-
[30] RENBARGER J L，MCCAMMACK K C，ROUSE C E， macol，2007，59（6）：703-709.
et al. Effect of race on vincristine-associated neurotoxicity [41] SIMOENS C，LARDON F，PAUWELS B，et al. Compara-
in pediatric acute lymphoblastic leukemia patients[J]. Pe- tive study of the radiosensitizing and cell cycle effects of
diatr Blood Cancer，2008，50（4）：769-771. vinflunine and vinorelbine，in vitro[J]. BMC Cancer，
[31] PÉTAIN A，ZHONG D F，CHEN X Y，et al. Effect of eth- 2008，8：65.
nicity on vinorelbine pharmacokinetics：a population phar- [42] HARADA H，SETO T，IGAWA S，et al. Phase Ⅰ results
macokinetics analysis[J]. Cancer Chemother Pharmacol， of vinorelbine with concurrent radiotherapy in elderly pa-
2019，84（2）：373-382. tients with unresectable，locally advanced non-small-cell
[32] BONNETERRE J，CHEVALIER B，FOCAN C，et al. lung cancer：west Japan Thoracic Oncology Group
Phase Ⅰ and pharmacokinetic study of weekly oral therapy （WJTOG3005-DI）[J]. Int J Radiat Oncol Biol Phys，
with vinorelbine in patients with advanced breast cancer 2012，82（5）：1777-1782.
（ABC）[J]. Ann Oncol，2001，12（12）：1683-1691. [43] ELHARRAR X，BARBOLOSI D，CICCOLINI J，et al. A
[33] GUSELLA M，PASINI F，CARUSO D，et al. Clinical out- phase Ⅰa/Ⅰb clinical trial of metronomic chemotherapy
comes of oral metronomic vinorelbine in advanced based on a mathematical model of oral vinorelbine in me-
non-small cell lung cancer：correlations with pharmacoki- tastatic non-small cell lung cancer and malignant pleural
netics and MDR1 polymorphisms[J]. Cancer Chemother mesothelioma：rationale and study protocol[J]. BMC Can-
Pharmacol，2019，83（3）：493-500. cer，2016，16：278.
[34] BRIASOULIS E，PAPPAS P，PUOZZO C，et al. Dose- [44] KNEZEVIC C E，CLARKE W. Cancer chemotherapy：the
ranging study of metronomic oral vinorelbine in patients case for therapeutic drug monitoring[J]. Ther Drug Monit，
with advanced refractory cancer[J]. Clin Cancer Res， 2020，42（1）：6-19.
2009，15（20）：6454-6461. [45] HOUY N，LE GRAND F. Optimal dynamic regimens with
[35] PASINI F，BARILE C，CARUSO D，et al. Oral Metrono- artificial intelligence：the case of temozolomide[J]. PLoS
mic Vinorelbine（OMV）in elderly or pretreated patients One，2018，13（6）：e0199076.
with advanced non small cell lung cancer：outcome and [46] BARLESI F，IMBS D C，TOMASINI P，et al. Mathemati-
pharmacokinetics in the real world[J]. Invest New Drugs， cal modeling for phase Ⅰcancer trials：a study of metro-
2018，36（5）：927-932. nomic vinorelbine for advanced non-small cell lung can-
[36] BRIASOULIS E，ARAVANTINOS G，KOUVATSEAS G， cer（NSCLC）and mesothelioma patients[J]. Oncotarget，
et al. Dose selection trial of metronomic oral vinorelbine 2017，8（29）：47161-47166.
monotherapy in patients with metastatic cancer：a Hellenic [47] CICCOLINI J，BARBOLOSI D，MEILLE C，et al. Phar-
cooperative oncology group clinical translational study[J]. macokinetics and pharmacodynamics-based mathematical
BMC Cancer，2013，13：263. modeling identifies an optimal protocol for metronomic
[37] CYBULSKA-STOPA B，ZIOBRO M，SKOCZEK M， chemotherapy[J]. Cancer Res，2017，77（17）：4723-4733.
et al. Evaluation of vinorelbine-based chemotherapy as [48] WONG M，BALLEINE R L，BLAIR E Y，et al. Predictors
the second or further-line treatment in patients with meta- of vinorelbine pharmacokinetics and pharmacodynamics
static breast cancer[J]. Contemp Oncol（Pozn），2013，17 in patients with cancer[J]. J Clin Oncol，2006，24（16）：
（1）：78-82. 2448-2455.
[38] MARTONI A A，MELOTTI B，SPERANDI F，et al. Hy- （收稿日期：2022-01-04 修回日期：2022-04-26）
brid（intravenous and oral）administration of vinorelbine （编辑：唐晓莲）
plus cisplatinum followed by oral vinorelbine as first-line

·1408 · China Pharmacy 2022 Vol. 33 No. 11 中国药房 2022年第33卷第11期